Black Health
Nucleoside reverse transcriptase inhibitors — HIV PrEP and treatment component HIV pre-exposure prophylaxis (PrEP) HIV treatment component

Tenofovir/Emtricitabine (Truvada (TDF/FTC), Descovy (TAF/FTC)) and Black patients

Brand names: Truvada (TDF/FTC), Descovy (TAF/FTC)

Last reviewed: Sources checked:

What Tenofovir/Emtricitabine does

Tenofovir/emtricitabine is a two-drug combination used both for HIV treatment (as a backbone with a third drug) and for HIV pre-exposure prophylaxis (PrEP) in people at risk of HIV acquisition. Truvada (TDF/FTC) is generic and widely covered; Descovy (TAF/FTC) is brand-name with a better renal/bone profile but limited FDA label indications.

What the evidence says for Black patients

PrEP is one of the sharpest equity failures in US healthcare:

  • In 2021 CDC surveillance data, Black Americans accounted for approximately 40 percent of new HIV diagnoses but received approximately 12 percent of PrEP prescriptions. Black women with PrEP indications are particularly under-treated (Harris et al., MMWR 2023; CDC NCHHSTP AtlasPlus).
  • The FDA approved Truvada for PrEP in 2012 based on iPrEx and Partners PrEP trial data. Subsequent real-world and demonstration-project data confirm efficacy across racial groups when adherence is achieved.
  • The Descovy vs Truvada question matters for Black patients: Descovy has less kidney and bone toxicity, which could matter given disproportionate CKD burden. But Descovy's FDA label does not include cisgender women's receptive-vaginal-sex exposure because the DISCOVER trial didn't include them — a direct gap that disadvantages Black women who were under-represented in the pivotal trial.
  • Ready, Set, PrEP federal program provides PrEP at no cost to uninsured patients. DHHS Ending the HIV Epidemic initiative targets 57 jurisdictions including many Southern states with high Black HIV prevalence.
  • Cabotegravir long-acting injectable (Apretude) offers an every-2-month alternative for patients with adherence challenges or stigma barriers to daily pills.

For HIV treatment, tenofovir/emtricitabine + integrase inhibitor is a standard backbone. Dolutegravir-based regimens are preferred — see Biktarvy and Tivicay pages.

Common alternatives

Cabotegravir IM every 2 months for PrEP. For treatment: bictegravir/TAF/FTC (Biktarvy) single-tablet regimen; dolutegravir plus other backbone agents.

Side effects

  • TDF form: reduced bone density, kidney function decline
  • TAF form: weight gain, elevated lipids, fewer renal/bone effects
  • GI upset, early nausea
  • Lactic acidosis (rare)
  • Hepatitis B flare if discontinued in HBV-coinfected patient

Factors that affect adherence

Daily pill adherence is the central issue for PrEP efficacy; alternative dosing ('2-1-1' for MSM, cabotegravir IM) can help. Generic Truvada costs pennies but the clinic visits, HIV/STI tests, and renal labs every 3 months are the real burden — telehealth PrEP and pharmacist-prescribed PrEP expand access in some states.

Questions to ask your doctor

Bring this list to your next appointment.

  • Am I a candidate for PrEP, and do I prefer daily pill or injectable every 2 months?
  • Should I be on Truvada (TDF) or Descovy (TAF) — and given the receptive-vaginal indication gap, does it matter for me?
  • Can I enroll in Ready, Set, PrEP if I'm uninsured?
  • Is my local clinic part of Ending the HIV Epidemic?

References

  1. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men (iPrEx). NEJM. 2010;363:2587–2599. PMID 21091279.
  2. Centers for Disease Control and Prevention. HIV Surveillance Report, 2021. Diagnoses of HIV Infection in the United States and Dependent Areas. https://www.cdc.gov/hiv/library/reports/hiv-surveillance.html
  3. Harris NS, Johnson AS, Huang YA, et al. Vital Signs: Status of Human Immunodeficiency Virus Testing, Viral Suppression, and HIV Preexposure Prophylaxis — United States, 2013–2018. MMWR. 2019;68:1117–1123.
  4. Mayer KH, Molina JM, Thompson MA, et al. Emtricitabine and tenofovir alafenamide vs. emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER). Lancet. 2020;396:239–254. PMID 32711800.
  5. U.S. Food and Drug Administration. Truvada, Descovy labels. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021752s063lbl.pdf

Medical disclaimer

This page is patient education, not prescribing guidance. It summarizes the published evidence about how this medication has been studied in Black patients — it is not a substitute for the judgment of your personal clinician. Never start, stop, or change a prescription based on something you read here. If you have questions about your medication, call your prescriber or pharmacist. For emergencies, call 911.

Read our editorial standards for how we source, review, and update these pages.